Topics: Dementia

It has now been a full ten years since the first of the second-generation cholinesterase inhibitors (CIs), Aricept (donepezil) was approved for Alzheimer’s dementia.

Topics: Dementia

A 70-year old man comes into your office and asks: “Doctor, I keep misplacing my keys-am I getting Alzheimer’s?” You detect the note of anxiety in his voice, and you want to give an answer, and soon.

Topics: Antipsychotics | Dementia | Depressive Disorder

Why don’t we start with the issue of agitation? The question in many psychiatrists’ minds is how seriously we should take the FDA advisory about the dangers of atypical antipsychotics?

Topics: Antidepressants | Anxiety Disorder

The largest and most rigorous study to date on the treatment of bipolar depression was just published in the New England Journal of Medicine. The study, conducted as part of the NIMH-funded Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), enrolled a total of 366 subjects with either bipolar I or II disorder during a major depressive episode.

Topics: ADHD

On February 21, 2007, the FDA directed all manufacturers of stimulants to develop Medication Guides for patients, spelling out, in non-technical language, the dangers of taking these medications.

Topics: Antipsychotics

We’ve known for some time now that clozapine and Zyprexa (olanzapine) cause the most weight gain of any antipsychotic, but we didn’t know the actual mechanism – until now.

Topics: Brain Devices

In the February issue of TCPR, we reported a recent FDA panel’s opinion that rTMS (repetitive transcranial magnetic stimulation) was relatively ineffective for treatment-resistant depression. The type of rTMS that has been tested for depression generally involves 10 Hz (ten pulses per second).